Histone Deacetylases and Their Inhibition in Candida Species

Area of Science:

• Medical Mycology
• Molecular Biology
• Drug Discovery

Background:

• Invasive fungal infections pose a significant global health threat, comparable to tuberculosis and malaria.
• Current antifungal treatments are limited to four drug classes, with emerging drug resistance posing a major challenge.
• Fungal adaptation to antifungal drugs involves transcriptional regulation, with histone modifications playing a key role.

Purpose of the Study:

• To review the role of histone deacetylases (HDACs) in fungal pathogenesis.
• To explore the therapeutic potential of HDAC inhibitors against Candida species.
• To highlight the clinical evaluation of HDAC inhibitors for invasive candidiasis.

Main Methods:

• Review of existing literature on HDACs and their inhibitors in Candida species.
• Analysis of in vitro and in vivo studies correlating pathogenic effects with HDAC inhibition.
• Examination of recent clinical trial data for HDAC inhibitors in treating invasive candidiasis.

Main Results:

• HDAC inhibition effectively limits fungal development, virulence, biofilm formation, and dissemination.
• HDAC inhibitors enhance the efficacy of existing antifungal drugs against Candida species.
• Studies show a correlation between in vitro and in vivo pathogenic effects and HDAC activity.

Conclusions:

• HDAC inhibitors represent a promising therapeutic strategy for invasive candidiasis.
• Targeting HDACs can overcome drug resistance and improve treatment outcomes.
• Further clinical evaluation is warranted to establish HDAC inhibitors as a viable treatment option.